SE503174C2 - Ciclosporinkristallformer, förfarande för dess framställning, farmaceutiska kompositioner innehållande densamma samt dess användning - Google Patents

Ciclosporinkristallformer, förfarande för dess framställning, farmaceutiska kompositioner innehållande densamma samt dess användning

Info

Publication number: SE503174C2
Authority: SE; Sweden
Prior art keywords: ciclosporin; iii; crystal form; orthorhombic; particle size
Prior art date: 1987-12-21

Application number

SE8804570A

Other languages

English (en)

Swedish (sv)

Other versions

SE8804570D0 (sv

SE8804570L (sv

Inventor

Danielle Giron

Martin List

Friedrich Richter

Yasuyuki Uike

Hans Peter Weber

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-21

Filing date

1988-12-19

Publication date

1996-04-15

1988-12-19 Application filed by Sandoz Ag filed Critical Sandoz Ag

1988-12-19 Publication of SE8804570D0 publication Critical patent/SE8804570D0/xx

1989-06-22 Publication of SE8804570L publication Critical patent/SE8804570L/

1996-04-15 Publication of SE503174C2 publication Critical patent/SE503174C2/sv

Links

229960001265 ciclosporin Drugs 0.000 title claims abstract description 117
108010036949 Cyclosporine Proteins 0.000 title claims abstract description 116
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 115
239000013078 crystal Substances 0.000 title claims abstract description 52
238000000034 method Methods 0.000 title claims abstract description 42
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
230000008569 process Effects 0.000 title claims abstract description 11
238000002360 preparation method Methods 0.000 title claims description 29
239000000203 mixture Substances 0.000 claims abstract description 83
230000000699 topical effect Effects 0.000 claims abstract description 26
239000007924 injection Substances 0.000 claims abstract description 20
238000002347 injection Methods 0.000 claims abstract description 20
238000004519 manufacturing process Methods 0.000 claims abstract description 10
239000004480 active ingredient Substances 0.000 claims abstract description 5
239000002245 particle Substances 0.000 claims description 57
239000000243 solution Substances 0.000 claims description 13
238000002425 crystallisation Methods 0.000 claims description 12
230000008025 crystallization Effects 0.000 claims description 12
239000007788 liquid Substances 0.000 claims description 10
239000000463 material Substances 0.000 claims description 8
239000003085 diluting agent Substances 0.000 claims description 4
238000002441 X-ray diffraction Methods 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
238000001802 infusion Methods 0.000 claims description 3
229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
239000002260 anti-inflammatory agent Substances 0.000 claims description 2
230000001506 immunosuppresive effect Effects 0.000 claims description 2
229940125721 immunosuppressive agent Drugs 0.000 claims description 2
239000003018 immunosuppressive agent Substances 0.000 claims description 2
239000000284 extract Substances 0.000 claims 1
239000013080 microcrystalline material Substances 0.000 claims 1
239000012453 solvate Substances 0.000 abstract description 12
238000011282 treatment Methods 0.000 description 42
239000000047 product Substances 0.000 description 30
201000004681 Psoriasis Diseases 0.000 description 22
-1 glycerol-polyethylene glycol esters Chemical class 0.000 description 21
229920001223 polyethylene glycol Polymers 0.000 description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
201000010099 disease Diseases 0.000 description 18
239000000902 placebo Substances 0.000 description 18
229940068196 placebo Drugs 0.000 description 18
238000012360 testing method Methods 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
239000002202 Polyethylene glycol Substances 0.000 description 14
239000003814 drug Substances 0.000 description 14
239000000499 gel Substances 0.000 description 13
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
230000000694 effects Effects 0.000 description 12
229940079593 drug Drugs 0.000 description 11
238000002560 therapeutic procedure Methods 0.000 description 11
229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 10
206010052428 Wound Diseases 0.000 description 9
208000027418 Wounds and injury Diseases 0.000 description 9
239000004094 surface-active agent Substances 0.000 description 9
206010015150 Erythema Diseases 0.000 description 8
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
239000002904 solvent Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 8
238000005809 transesterification reaction Methods 0.000 description 8
239000006071 cream Substances 0.000 description 7
239000013081 microcrystal Substances 0.000 description 7
229920000136 polysorbate Polymers 0.000 description 7
230000009467 reduction Effects 0.000 description 7
235000015112 vegetable and seed oil Nutrition 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
230000036576 dermal application Effects 0.000 description 6
238000009826 distribution Methods 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
231100000321 erythema Toxicity 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000006872 improvement Effects 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
235000019271 petrolatum Nutrition 0.000 description 6
229940068886 polyethylene glycol 300 Drugs 0.000 description 6
239000003381 stabilizer Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 5
239000004264 Petrolatum Substances 0.000 description 5
239000004698 Polyethylene Substances 0.000 description 5
239000004599 antimicrobial Substances 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
239000003925 fat Substances 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
239000011630 iodine Substances 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
239000006186 oral dosage form Substances 0.000 description 5
229940066842 petrolatum Drugs 0.000 description 5
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 5
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 5
229960003415 propylparaben Drugs 0.000 description 5
239000000126 substance Substances 0.000 description 5
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
201000004384 Alopecia Diseases 0.000 description 4
206010003645 Atopy Diseases 0.000 description 4
201000004624 Dermatitis Diseases 0.000 description 4
206010048768 Dermatosis Diseases 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
229920001214 Polysorbate 60 Polymers 0.000 description 4
206010046851 Uveitis Diseases 0.000 description 4
231100000360 alopecia Toxicity 0.000 description 4
235000019445 benzyl alcohol Nutrition 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000004359 castor oil Substances 0.000 description 4
235000019438 castor oil Nutrition 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000001816 cooling Methods 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
230000002500 effect on skin Effects 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
150000002170 ethers Chemical class 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
230000035784 germination Effects 0.000 description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
238000000227 grinding Methods 0.000 description 4
238000000265 homogenisation Methods 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
235000008390 olive oil Nutrition 0.000 description 4
239000004006 olive oil Substances 0.000 description 4
229940100688 oral solution Drugs 0.000 description 4
238000000634 powder X-ray diffraction Methods 0.000 description 4
238000012545 processing Methods 0.000 description 4
208000017520 skin disease Diseases 0.000 description 4
239000007787 solid Substances 0.000 description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
239000008158 vegetable oil Substances 0.000 description 4
LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 3
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
208000009137 Behcet syndrome Diseases 0.000 description 3
229930105110 Cyclosporin A Natural products 0.000 description 3
206010012442 Dermatitis contact Diseases 0.000 description 3
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 3
208000003556 Dry Eye Syndromes Diseases 0.000 description 3
206010013774 Dry eye Diseases 0.000 description 3
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 3
235000019483 Peanut oil Nutrition 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
208000003251 Pruritus Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229920002125 Sokalan® Polymers 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
238000000889 atomisation Methods 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
208000010247 contact dermatitis Diseases 0.000 description 3
RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 3
229930182912 cyclosporin Natural products 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
238000010586 diagram Methods 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
230000001815 facial effect Effects 0.000 description 3
235000019197 fats Nutrition 0.000 description 3
239000008394 flocculating agent Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000006911 nucleation Effects 0.000 description 3
238000010899 nucleation Methods 0.000 description 3
239000003921 oil Substances 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000000312 peanut oil Substances 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000005096 rolling process Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000011200 topical administration Methods 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
235000019489 Almond oil Nutrition 0.000 description 2
208000002691 Choroiditis Diseases 0.000 description 2
206010010741 Conjunctivitis Diseases 0.000 description 2
206010012438 Dermatitis atopic Diseases 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
235000019482 Palm oil Nutrition 0.000 description 2
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
208000003971 Posterior uveitis Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
239000008168 almond oil Substances 0.000 description 2
201000008937 atopic dermatitis Diseases 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000008859 change Effects 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000000084 colloidal system Substances 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000002996 emotional effect Effects 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
230000009969 flowable effect Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
239000012051 hydrophobic carrier Substances 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000036512 infertility Effects 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
230000007803 itching Effects 0.000 description 2
229940057995 liquid paraffin Drugs 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
239000003607 modifier Substances 0.000 description 2
239000002540 palm oil Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
210000004197 pelvis Anatomy 0.000 description 2
229920001281 polyalkylene Polymers 0.000 description 2
229920001515 polyalkylene glycol Polymers 0.000 description 2
239000008389 polyethoxylated castor oil Substances 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
229940068965 polysorbates Drugs 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000001384 succinic acid Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000008719 thickening Effects 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
238000005690 transetherification reaction Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
241001550224 Apha Species 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
235000017060 Arachis glabrata Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000018262 Arachis monticola Nutrition 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
241000689227 Cora <basidiomycete fungus> Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
208000035874 Excoriation Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
201000002287 Keratoconus Diseases 0.000 description 1
206010066295 Keratosis pilaris Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
206010024438 Lichenification Diseases 0.000 description 1
241000556720 Manga Species 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
206010033546 Pallor Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
108010002885 Polygeline Proteins 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
206010040867 Skin hypertrophy Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
238000004279 X-ray Guinier Methods 0.000 description 1
IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000001944 accentuation Effects 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000009285 allergic inflammation Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
UIERETOOQGIECD-ARJAWSKDSA-N angelic acid group Chemical group C(\C(\C)=C/C)(=O)O UIERETOOQGIECD-ARJAWSKDSA-N 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
230000000884 anti-protozoa Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
229940074979 cetyl palmitate Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000011970 concomitant therapy Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000005562 fading Methods 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
210000003746 feather Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
206010021198 ichthyosis Diseases 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
230000006651 lactation Effects 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
231100000381 nephrotoxic Toxicity 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
210000002445 nipple Anatomy 0.000 description 1
238000006396 nitration reaction Methods 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
201000005111 ocular hyperemia Diseases 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000003209 petroleum derivative Substances 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
206010035111 pityriasis alba Diseases 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000009597 pregnancy test Methods 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
239000011435 rock Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
230000037380 skin damage Effects 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
229940046303 sodium cetostearyl sulfate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
229940084026 sodium valproate Drugs 0.000 description 1
CLBALUNQCMWJSU-UHFFFAOYSA-L sodium;hexadecyl sulfate;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O CLBALUNQCMWJSU-UHFFFAOYSA-L 0.000 description 1
238000000527 sonication Methods 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
235000011078 sorbitan tristearate Nutrition 0.000 description 1
239000001589 sorbitan tristearate Substances 0.000 description 1
229960004129 sorbitan tristearate Drugs 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000035900 sweating Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
201000005539 vernal conjunctivitis Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

SE8804570A 1987-12-21 1988-12-19 Ciclosporinkristallformer, förfarande för dess framställning, farmaceutiska kompositioner innehållande densamma samt dess användning SE503174C2 (sv)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US13623087A	1987-12-21	1987-12-21
US17261388A	1988-03-24	1988-03-24
US21254888A	1988-06-28	1988-06-28

Publications (3)

Publication Number	Publication Date
SE8804570D0 SE8804570D0 (sv)	1988-12-19
SE8804570L SE8804570L (sv)	1989-06-22
SE503174C2 true SE503174C2 (sv)	1996-04-15

Family

ID=27384838

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8804570A SE503174C2 (sv)	1987-12-21	1988-12-19	Ciclosporinkristallformer, förfarande för dess framställning, farmaceutiska kompositioner innehållande densamma samt dess användning

Country Status (27)

Country	Link
JP (1)	JPH0791316B2 (fr)
KR (1)	KR100188305B1 (fr)
AT (1)	AT403163B (fr)
AU (1)	AU626274B2 (fr)
BE (1)	BE1002665A4 (fr)
CA (1)	CA1341396C (fr)
CH (1)	CH677926A5 (fr)
CY (1)	CY1799A (fr)
DE (1)	DE3843054C2 (fr)
DK (1)	DK175220B1 (fr)
ES (1)	ES2012580A6 (fr)
FI (1)	FI89065C (fr)
FR (1)	FR2624863B1 (fr)
GB (1)	GB2211848B (fr)
GR (1)	GR1002486B (fr)
HK (1)	HK102894A (fr)
HU (1)	HU203564B (fr)
IE (1)	IE62006B1 (fr)
IL (1)	IL88719A0 (fr)
IT (1)	IT1235356B (fr)
LU (1)	LU87409A1 (fr)
MY (1)	MY103943A (fr)
NL (1)	NL195096C (fr)
NO (1)	NO177228C (fr)
NZ (1)	NZ227384A (fr)
SE (1)	SE503174C2 (fr)
SG (1)	SG99494G (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5639724A (en)	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
US6007840A (en) *	1988-09-16	1999-12-28	Novartis Ag	Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) *	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
US7081445B2 (en)	1989-02-20	2006-07-25	Novartis Ag	Cyclosporin galenic forms
US5294604A (en) *	1989-12-20	1994-03-15	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating ocular diseases by periocular administration of cyclosporine A or G
GB9105705D0 (en) *	1991-03-18	1991-05-01	Sandoz Ltd	Improvements in or relating to organic compounds
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
SG45449A1 (en) *	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
DK0589843T3 (da)	1992-09-25	2002-04-02	Novartis Ag	Cyclosporinholdige farmaceutiske præparater
ES2177652T3 (es)	1994-11-03	2002-12-16	Novartis Ag	Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion.
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
US5766629A (en)	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
DE19544507B4 (de)	1995-11-29	2007-11-15	Novartis Ag	Cyclosporin enthaltende Präparate
US6262054B1 (en)	1996-02-01	2001-07-17	Sloan-Kettering Institute Of Cancer Research	Combination therapy method for treating breast cancer using edatrexate
KR20050084502A (ko)	1997-01-30	2005-08-26	노파르티스 아게	오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
TW581681B (en)	1998-02-20	2004-04-01	Nektar Therapeutics	Liquid crystal forms of cyclosporin
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
CN100548271C (zh)	2004-01-20	2009-10-14	阿勒根公司	用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物
CN1763084B (zh) *	2005-10-11	2010-04-21	山东新时代药业有限公司	高纯度环孢菌素a的制备方法
BR112013030554B1 (pt) *	2011-05-27	2020-12-15	Allergan, Inc.	Forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma
RU2641963C2 (ru) *	2011-11-15	2018-01-23	Аллерган, Инк.	Взвеси циклоспорина а формы 2
US20130123194A1 (en) *	2011-11-15	2013-05-16	Allergan, Inc.	Autoclavable suspensions of cyclosporin a form 2
CA2856034C (fr) *	2011-11-15	2017-12-12	Allergan, Inc.	Forme 2 de cyclosporine a et methode de fabrication associee
US8785394B2 (en) *	2011-11-15	2014-07-22	Allergan, Inc.	Sustained action formulation of cyclosporin form 2
TW202430537A (zh) *	2022-10-20	2024-08-01	日商中外製藥股份有限公司	環狀胜肽的結晶的製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH614931A5 (fr) *	1975-11-04	1979-12-28	Sandoz Ag
CH640519A5 (en) *	1976-04-09	1984-01-13	Sandoz Ag	Process for preparing a modified form of the antibiotic S 7481/F-1
US4117118A (en) *	1976-04-09	1978-09-26	Sandoz Ltd.	Organic compounds
DE2819094A1 (de) *	1977-05-10	1978-11-23	Sandoz Ag	Cyclosporin-derivate, ihre verwendung und herstellung
CH637124A5 (en) *	1978-10-18	1983-07-15	Sandoz Ag	Antibiotic, its preparation and use

1988
- 1988-12-09 HU HU886374A patent/HU203564B/hu unknown
- 1988-12-19 NO NO885625A patent/NO177228C/no unknown
- 1988-12-19 AU AU27055/88A patent/AU626274B2/en not_active Expired
- 1988-12-19 FI FI885869A patent/FI89065C/fi not_active IP Right Cessation
- 1988-12-19 IE IE377988A patent/IE62006B1/en not_active IP Right Cessation
- 1988-12-19 CH CH4687/88A patent/CH677926A5/de not_active IP Right Cessation
- 1988-12-19 SE SE8804570A patent/SE503174C2/sv not_active IP Right Cessation
- 1988-12-19 NZ NZ227384A patent/NZ227384A/xx unknown
- 1988-12-19 DK DK198807054A patent/DK175220B1/da not_active IP Right Cessation
- 1988-12-19 IL IL88719A patent/IL88719A0/xx unknown
- 1988-12-19 FR FR888816886A patent/FR2624863B1/fr not_active Expired - Lifetime
- 1988-12-19 GB GB8829556A patent/GB2211848B/en not_active Expired - Lifetime
- 1988-12-20 LU LU87409A patent/LU87409A1/fr unknown
- 1988-12-20 KR KR1019880017194A patent/KR100188305B1/ko not_active Expired - Lifetime
- 1988-12-20 IT IT8848690A patent/IT1235356B/it active
- 1988-12-20 BE BE8801421A patent/BE1002665A4/fr not_active IP Right Cessation
- 1988-12-20 JP JP63321857A patent/JPH0791316B2/ja not_active Expired - Lifetime
- 1988-12-20 AT AT0309588A patent/AT403163B/de not_active IP Right Cessation
- 1988-12-20 GR GR880100850A patent/GR1002486B/el not_active IP Right Cessation
- 1988-12-21 CA CA000586611A patent/CA1341396C/fr not_active Expired - Fee Related
- 1988-12-21 DE DE3843054A patent/DE3843054C2/de not_active Expired - Lifetime
- 1988-12-21 NL NL8803125A patent/NL195096C/nl active Search and Examination
- 1988-12-21 ES ES8803887A patent/ES2012580A6/es not_active Expired - Lifetime
- 1988-12-21 MY MYPI88001495A patent/MY103943A/en unknown
1994
- 1994-07-21 SG SG99494A patent/SG99494G/en unknown
- 1994-09-22 HK HK102894A patent/HK102894A/xx not_active IP Right Cessation
1995
- 1995-02-17 CY CY179995A patent/CY1799A/en unknown

Also Published As

Publication number	Publication date
NZ227384A (en)	1991-09-25
DK705488A (da)	1989-06-22
CH677926A5 (fr)	1991-07-15
LU87409A1 (fr)	1989-07-07
NL195096C (nl)	2004-02-09
DK175220B1 (da)	2004-07-12
JPH01211598A (ja)	1989-08-24
FR2624863A1 (fr)	1989-06-23
IT8848690A0 (it)	1988-12-20
SE8804570D0 (sv)	1988-12-19
KR100188305B1 (ko)	1999-06-01
BE1002665A4 (fr)	1991-04-30
GR1002486B (el)	1996-12-09
GR880100850A (el)	1994-03-31
MY103943A (en)	1993-10-30
HK102894A (en)	1994-09-30
IT1235356B (it)	1992-06-30
CY1799A (en)	1995-02-17
CA1341396C (fr)	2002-11-05
NL8803125A (nl)	1989-07-17
AT403163B (de)	1997-11-25
ES2012580A6 (es)	1990-04-01
JPH0791316B2 (ja)	1995-10-04
FR2624863B1 (fr)	1991-04-26
NO885625D0 (no)	1988-12-19
GB2211848B (en)	1991-11-06
ATA309588A (de)	1997-04-15
FI885869A0 (fi)	1988-12-19
FI89065C (fi)	1993-09-30
SE8804570L (sv)	1989-06-22
DE3843054A1 (de)	1989-07-27
AU626274B2 (en)	1992-07-30
DK705488D0 (da)	1988-12-19
NO885625L (no)	1989-06-22
IL88719A0 (en)	1989-07-31
IE62006B1 (en)	1994-12-14
AU2705588A (en)	1989-06-22
FI885869L (fi)	1989-06-22
FI89065B (fi)	1993-04-30
IE883779L (en)	1989-06-21
KR890009975A (ko)	1989-08-05
SG99494G (en)	1994-10-28
HUT49893A (en)	1989-11-28
NO177228B (no)	1995-05-02
DE3843054C2 (de)	2003-08-21
NO177228C (no)	1995-08-09
HU203564B (en)	1991-08-28
GB8829556D0 (en)	1989-02-08
GB2211848A (en)	1989-07-12

Legal Events

Date	Code	Title	Description
2009-02-17	NUG	Patent has lapsed

Publication	Publication Date	Title
FI89065C (fi)	1993-09-30	Foerfarande foer framstaellning av en ny siklosporin kristallform
AT403435B (de)	1998-02-25	Cyclosporin enthaltende pharmazeutische zusammensetzung
ES2292782T3 (es)	2008-03-16	Nueva composicion farmaceutica.
DE69414840T2 (de)	1999-04-22	Akzeptabele pharmazeutische zusammensetzung enthaltend einen alkohol und einen hydrophalischen wirkstoff
US6486124B2 (en)	2002-11-26	Cyclosporin compositions and process therefor
DE69631601T2 (de)	2004-12-16	Pharmazeutische zusammensetzungen von cyclosporine mit einer polyethoxylierten hydroxy-fettsaäure
JP2828387B2 (ja)	1998-11-25	シクロスポリン含有医薬組成物
JPH0611703B2 (ja)	1994-02-16	新規シクロスポリン製剤
CN104902875A (zh)	2015-09-09	四环素局部制剂、其制备及用途
EP1249230B1 (fr)	2003-11-05	Microémulsions et préconcentrés en microémulsion comprenant de la coenzyme Q10
SE503279C2 (sv)	1996-05-13	Vattenlösliga monoestrar som solubiliseringsmedel för farmakologiskt aktiva föreningar och farmaceutiska excipienter
CZ847488A3 (en)	1995-02-15	Process for preparing cyclosporin a
KR100267149B1 (ko)	2000-09-15	사이클로스포린을 함유하는 약학 조성물
KR100256007B1 (ko)	2000-05-01	사이클로스포린을 함유하는 약학 조성물
HU212727B (en)	1996-10-28	Process for producing pharmaceutical compositions in form of microemulsion-prae-concentrate or microemulsion containing cyclosporin(s) as active component